cycD1/CCND1 Cancer Research Results

cycD1/CCND1, cyclin D1 pathway: Click to Expand ⟱
Source:
Type:
Also called CCND1 Gatekeeper of Cell-Cycle Commitment
The main function of cyclin D1 is to maintain cell cycle and to promote cell proliferation. Cyclin D1 is a key regulatory protein involved in the cell cycle, particularly in the transition from the G1 phase to the S phase. It is part of the cyclin-dependent kinase (CDK) complex, where it binds to CDK4 or CDK6 to promote cell cycle progression.
Cyclin D1 is crucial for the regulation of the cell cycle. Overexpression or dysregulation of cyclin D1 can lead to uncontrolled cell proliferation, a hallmark of cancer.
Cyclin D1 is often found to be overexpressed in various cancers.
Cyclin D1 can interact with tumor suppressor proteins, such as retinoblastoma (Rb). When cyclin D1 is overexpressed, it can lead to the phosphorylation and inactivation of Rb, releasing E2F transcription factors that promote the expression of genes required for DNA synthesis and cell cycle progression.
Cyclin D1 is influenced by various signaling pathways, including the PI3K/Akt and MAPK pathways, which are often activated in cancer.
In some cancers, high levels of cyclin D1 expression have been associated with poor prognosis, making it a potential biomarker for cancer progression and treatment response.
HCC, Hepatocellular Carcinoma: Click to Expand ⟱
Hepatocellular Carcinoma
Scientific Papers found: Click to Expand⟱
2423- 2DG,  SRF,    2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells
- in-vitro, HCC, NA
ChemoSen↑, TumCP↓, cycD1/CCND1↓, MMP9↓,
276- ALA,    Alpha lipoic acid diminishes migration and invasion in hepatocellular carcinoma cells through an AMPK-p53 axis
- in-vitro, HCC, HepG2 - in-vitro, HCC, Hep3B
P53↑, EMT↓, AMPK↑, cycD1/CCND1↓, TumCMig↓,
5891- CAR,  SRF,    Carvacrol enhances anti-tumor activity and mitigates cardiotoxicity of sorafenib in thioacetamide-induced hepatocellular carcinoma model through inhibiting TRPM7
- in-vivo, HCC, NA
eff↑, OS↑, hepatoP↑, AFP↓, NOTCH↓, cycD1/CCND1↓, Bcl-xL↑, Casp3↑, TRPM7↓, Dose↝,
5225- EMD,    Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3
- vitro+vivo, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
STAT3↓, Akt↓, cSrc↓, JAK1↓, JAK2↓, SHP1↑, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, Mcl-1↓, survivin↓, VEGF↓, TumCP↓, Casp3↑, cl‑PARP↑, ChemoSen↑, XIAP↓,
826- GAR,    Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo
- vitro+vivo, HCC, HepG2 - vitro+vivo, Liver, HUH7
STAT3↓, TumCP↓, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, Mcl-1↓, survivin↓, VEGF↓, TumCCA↑, TumVol↓,
3276- Lyco,    Lycopene modulates cellular proliferation, glycolysis and hepatic ultrastructure during hepatocellular carcinoma
- in-vivo, HCC, NA
G6PD↓, PCNA↓, cycD1/CCND1↓, P21↑, Hif1a↓, Glycolysis↓,
1267- NCL,    Niclosamide suppresses migration of hepatocellular carcinoma cells and downregulates matrix metalloproteinase-9 expression
- in-vitro, HCC, NA
TumCP↓, cycD1/CCND1↓, MMP9↓, TumCMig↓,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics ⓘ

XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   G6PD↓, 1,   Glycolysis↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Bcl-2↓, 2,   Bcl-xL↓, 2,   Bcl-xL↑, 1,   Casp3↑, 2,   Mcl-1↓, 2,   survivin↓, 2,  

Kinase & Signal Transduction ⓘ

cSrc↓, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,   cl‑PARP↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 7,   P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   NOTCH↓, 1,   SHP1↑, 1,   STAT3↓, 2,   TRPM7↓, 1,  

Migration ⓘ

MMP9↓, 2,   TumCMig↓, 2,   TumCP↓, 4,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,   VEGF↓, 2,  

Immune & Inflammatory Signaling ⓘ

JAK1↓, 1,   JAK2↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 2,   Dose↝, 1,   eff↑, 1,  

Clinical Biomarkers ⓘ

AFP↓, 1,  

Functional Outcomes ⓘ

hepatoP↑, 1,   OS↑, 1,   TumVol↓, 1,  
Total Targets: 37

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: cycD1/CCND1, cyclin D1 pathway
2 Sorafenib (brand name Nexavar)
1 2-DeoxyGlucose
1 Alpha-Lipoic-Acid
1 Carvacrol
1 Emodin
1 Garcinol
1 Lycopene
1 Niclosamide (Niclocide)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:10  Cells:%  prod#:%  Target#:73  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page